AF
EWTX icon

Amalgamated Financial’s Edgewise Therapeutics EWTX Stock Holding History

Amalgamated Financial’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$61K Buy
+6,299
New +$81.1K ﹤0.01% 2323

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Amalgamated Financial's EWTX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Edgewise Therapeutics (EWTX) in Q1 2022: 6,299 shares worth $61K. The stake represents ﹤0.01% of the portfolio and ranks #2323 among its holdings.

72 funds tracked by Wall St. Rank hold EWTX as of Q1 2022.

  • Amalgamated Financial held 6,299 shares of Edgewise Therapeutics worth $61K as of Q1 2022.
  • Edgewise Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Edgewise Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2323 holding.
  • 72 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.